“O.itemList.length” “- this.config.text.ariaShown
“This.config.text.ariaFermé”
By Natalia A. Ramos Miranda
SANTIAGO, 27 ago (Reuters) – An organization of South American presidents agreed on Thursday for percentages of data and coordinating access to imaginable COVID-19 vaccines to counter the virus that has the continent at hand, said the chancellor of Chile.
Andrés Allamand said that a coordinated technique for obtaining a vaccine through members of the Prosur block, comprising Chile, Argentina, Brazil, Colombia, Paraguay, Peru, Ecuador and Guyana, would be beneficial.
“A joint effort will bring benefits, in terms of access, amounts and guaranteed prices,” he said after the virtual assembly of presidents and chancellors.
Discussions reflect intensive studies of the position of emerging and emerging countries to ensure that their citizens have early and affordable COVID-19 vaccines.
More than vaccines around the world are recently being developed and tested, according to the World Health Organization, with 25 human clinical trials.
Vaccine trials, in addition to those developed through Johnson-Johnson, Sinovac and AstraZeneca, are already underway or are expected to begin within a while in Latin America, an existing pandemic focus.
Allamand said the block had discussed the production in Argentina and Mexico of the vaccine created through the British pharmaceutical company AstraZeneca, and the “very advanced” production paints in Brazil, and the prospect of those projects to gain advantages throughout the region.
He said Chile is also achieving its own international vaccine relations.
“In Chile we are following the progress of at least five projects and have contacted some of these particular laboratories and countries to access these vaccines at reasonable costs and as temporarily as possible,” he said.
Allamand said Prosur executives also agreed to coordinate the eventual reopening of their borders, establishing a technical commission that will report how this can be done within 10 days, adding potentially stricter access needs, such as a negative Covid-19 PCR test. . (Report through Natalia Ramos, written through Aislinn Laing; edited through Bernadette Baum)